← Back to Screener
Iridex Corp (IRIX)
Price$1.05
Favorite Metrics
Price vs S&P 500 (26W)-6.82%
Price vs S&P 500 (4W)-30.97%
Market Capitalization$18.17M
All Metrics
Book Value / Share (Quarterly)$0.29
P/TBV (Annual)5.33x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.58%
Cash Flow / Share (Quarterly)$-0.23
Price vs S&P 500 (YTD)-11.16%
Gross Margin (TTM)36.50%
Net Profit Margin (TTM)-8.42%
EPS (TTM)$-0.26
10-Day Avg Trading Volume1.25M
EPS Excl Extra (TTM)$-0.26
Revenue Growth (5Y)7.70%
EPS (Annual)$-0.26
ROI (Annual)-51.25%
Gross Margin (Annual)36.50%
Net Profit Margin (5Y Avg)-13.63%
Cash / Share (Quarterly)$0.35
Revenue Growth QoQ (YoY)7.80%
ROA (Last FY)-15.22%
Revenue Growth TTM (YoY)4.58%
EBITD / Share (TTM)$-0.24
ROE (5Y Avg)-136.36%
Operating Margin (TTM)-4.88%
Cash Flow / Share (Annual)$-0.44
P/B Ratio3.69x
P/B Ratio (Quarterly)4.26x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.30x
Net Interest Coverage (TTM)76.00x
ROA (TTM)-14.39%
EV / EBITDA (TTM)16.72x
EPS Incl Extra (Annual)$-0.26
Current Ratio (Annual)1.91x
Quick Ratio (Quarterly)1.18x
3-Month Avg Trading Volume0.22M
52-Week Price Return2.91%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.23
P/S Ratio (Annual)0.34x
Asset Turnover (Annual)1.81x
52-Week High$1.65
Operating Margin (5Y Avg)-12.76%
EPS Excl Extra (Annual)$-0.26
CapEx CAGR (5Y)-36.90%
Tangible BV CAGR (5Y)-25.62%
26-Week Price Return1.92%
Quick Ratio (Annual)1.18x
13-Week Price Return-19.70%
Total Debt / Equity (Annual)0.76x
Current Ratio (Quarterly)1.91x
Enterprise Value$15.88
Revenue / Share Growth (5Y)3.44%
Asset Turnover (TTM)1.71x
Book Value / Share Growth (5Y)-25.53%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.81x
Pretax Margin (Annual)-8.32%
Cash / Share (Annual)$0.35
3-Month Return Std Dev70.33%
Gross Margin (5Y Avg)41.10%
Net Income / Employee (TTM)$-0
ROE (Last FY)-90.15%
EPS Basic Excl Extra (Annual)$-0.26
P/FCF (TTM)1.49x
Receivables Turnover (TTM)7.74x
Total Debt / Equity (Quarterly)0.76x
EPS Incl Extra (TTM)$-0.26
Receivables Turnover (Annual)7.68x
ROI (TTM)-47.62%
P/S Ratio (TTM)0.34x
Pretax Margin (5Y Avg)-13.51%
Revenue / Share (Annual)$3.11
Tangible BV / Share (Annual)$0.23
Price vs S&P 500 (52W)-32.18%
Year-to-Date Return-7.02%
5-Day Price Return2.91%
EPS Normalized (Annual)$-0.26
ROA (5Y Avg)-20.44%
Net Profit Margin (Annual)-8.42%
Month-to-Date Return4.95%
Cash Flow / Share (TTM)$-0.34
EBITD / Share (Annual)$-0.26
Operating Margin (Annual)-4.88%
LT Debt / Equity (Annual)0.76x
ROI (5Y Avg)-80.46%
LT Debt / Equity (Quarterly)0.76x
EPS Basic Excl Extra (TTM)$-0.26
P/TBV (Quarterly)5.33x
P/B Ratio (Annual)4.26x
Inventory Turnover (TTM)3.43x
Pretax Margin (TTM)-8.32%
Book Value / Share (Annual)$0.29
Price vs S&P 500 (13W)-22.56%
Beta0.67x
P/FCF (Annual)2.27x
Revenue / Share (TTM)$3.06
ROE (TTM)-78.83%
52-Week Low$0.87
Analyst Recommendations
Dec 2024
Jan 2025
Mar 2026
Apr 2026
2.17
2.17
4.14
4.14
Industry Peers — Electromedical Equipment(29)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
IRIXIridex Corp | 0.34x | 7.70% | 36.50% | -4.88% | $1.05 |
MDTMedtronic plc | 3.13x | 3.01% | 65.16% | 17.00% | $85.00 |
MASIMasimo Corporation | 6.11x | 5.95% | 61.90% | 20.30% | $178.45 |
TMDXTransMedics Group, Inc. Common Stock | 6.56x | 88.21% | 59.92% | 17.93% | $113.13 |
LIVNLivaNova PLC Ordinary Shares | 2.59x | 8.24% | 68.04% | 14.09% | $65.81 |
ITGRInteger Holdings Corporation | 1.66x | 11.55% | 27.39% | 11.90% | $89.32 |
AXGNAxogen, Inc. Common Stock | 8.90x | 14.93% | 74.31% | -3.49% | $37.23 |
CNMDCONMED Corporation | 0.88x | 9.77% | 54.59% | 7.46% | $39.68 |
BLFSBioLife Solutions Inc. | 10.84x | 14.87% | 64.56% | -17.26% | $22.19 |
INMDInMode Ltd. Ordinary Shares | 2.51x | 12.45% | 78.54% | 23.05% | $14.57 |
CBLLCeriBell, Inc. Common Stock | 8.96x | — | 87.89% | -65.57% | $21.13 |
About
IRIDEX manufactures laser-based medical systems for ophthalmology, powered by proprietary Micropulse technology that provides competitive differentiation. The company generates revenue through sales of surgical consoles, delivery devices, glaucoma treatment systems, consumables, and support services, with additional exposure to veterinary and ENT markets. IRIDEX operates globally with primary revenue contributions from North America, Europe, and Asia/Pacific.